DaVita Inc Stock Soars 25% After DaVita Beats Q4 Results And Raises 2026 Outlook

DaVita reported Q4 revenue of $3.62 billion (nearly +10% YoY) and adjusted EPS of $3.40, beating Wall Street estimates on both top and bottom lines and driving a 24.57% intraday share jump to $138.51. Full-year results showed higher earnings and strong cash flow, supported by share repurchases and refinancing, while management issued 2026 guidance calling for adjusted earnings well above consensus, underpinned by resilience in dialysis operations, improving revenue per treatment and sustained free cash flow.

Analysis

Market structure: DaVita (DVA) is the primary beneficiary—strong 4Q and 2026 guidance lifts pricing power and underwriting for dialysis services while enabling continued buybacks that concentrate equity. Competitors (notably Fresenius Medical Care) and smaller clinic operators face margin pressure if DVA uses scale to negotiate better payer contracts or capture share in value-based programs; suppliers (dialysis equipment vendors) benefit from steady capex. Cross-asset: tighter DVA credit spreads and lower corporate bond yields are likely if free cash flow sustains; equity implied volatility will remain elevated near earnings windows, with negligible FX or commodity impacts.

Risk assessment: Key tail risks are regulatory (CMS reimbursement or ESRD policy changes) that could cut revenue per treatment 5–15% and reduce EPS >15%, operational (staff shortages increasing labor costs 200–400 bps of margin) and litigation/regulatory probes. Time buckets: immediate (days) - momentum/mean reversion after the 24% gap; short-term (weeks–months) - guidance re‑ratings and CMS commentary; long-term (quarters) - structural payer mix and reimbursement trends. Hidden dependencies include Medicaid/capitation contract renewals and dialysis unit utilization; catalysts are CMS rule releases, Q1 2026 trends, and major contract renewals.

Trade implications: Construct a core-long equity position sized 2–3% of portfolio in DVA with a 12‑month target $175 (~25% upside) and hard stop at $125 (≈10% downside). Implement a relative-value pair: long DVA vs short FMS.DE (Fresenius Medical Care) at 0.8x notional for 6–12 months to play execution/flow differences; unwind if spread tightens to <10% or reverses >5% in 30 days. Use options to manage entry: sell 30–45 day 10–15% OTM covered calls to collect premium and buy a 9–12 month 140/190 call spread (half equity size) to cap risk and participate in upside.

Contrarian angles: Consensus underestimates reimbursement volatility and the potential for multiple contraction after a large run-up—historly, post-earnings breakouts in services names revert 20–30% if follow-through metrics disappoint. The market may be overpaying for near-term guidance; buybacks can mask organic growth slowing. Triggers to flip bearish: QoQ revenue per treatment decline >3% or CMS draft that signals >5% reimbursement headwind within 60 days.

Key Decisions for Investors

• Establish a 2–3% long position in DVA around current levels (up to $140); set a 12‑month price target of $175 (~25% upside) and a stop-loss at $125 (≈10% downside).
• Initiate a pair trade: long DVA and short FMS.DE (Fresenius Medical Care) at 0.8x notional for a 6–12 month horizon; trim if the DVA–FMS spread narrows to <10% or if FMS outperforms DVA by >5% in 30 days.
• Sell 30–45 day covered calls 10–15% OTM against up to 50% of the equity position to monetize elevated IV; simultaneously buy a 9–12 month DVA 140/190 call spread sized to half the equity exposure to cap risk and retain upside.
• If within the next 60 days CMS issues draft rules implying >5% effective reimbursement cuts, or if revenue-per-treatment falls >3% QoQ in next quarterly report, reduce DVA exposure by 50% within 5 trading days.